Bank Julius Baer & Co. Ltd Zurich Sells 334,241 Shares of Johnson & Johnson (NYSE:JNJ)

Bank Julius Baer & Co. Ltd Zurich lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 16.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,662,194 shares of the company’s stock after selling 334,241 shares during the quarter. Johnson & Johnson makes up 0.8% of Bank Julius Baer & Co. Ltd Zurich’s portfolio, making the stock its 29th biggest position. Bank Julius Baer & Co. Ltd Zurich owned 0.07% of Johnson & Johnson worth $258,806,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Knuff & Co LLC lifted its holdings in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after buying an additional 64 shares during the period. Vertex Planning Partners LLC raised its position in shares of Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after acquiring an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its stake in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares during the last quarter. Denali Advisors LLC boosted its position in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after purchasing an additional 67 shares in the last quarter. Finally, Corepath Wealth Partners LLC grew its stake in Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after purchasing an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $166.81 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market cap of $401.61 billion, a P/E ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47. The business’s 50 day moving average price is $152.95 and its 200 day moving average price is $156.30.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is 74.59%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Barclays increased their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Bank of America raised their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday. Guggenheim lifted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Raymond James decreased their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.